This week, SW pharmaceutical and biological industry lost the CSI 300 index. From December 6 to December 10, 2021, the SW pharmaceutical and biological industry index rose by 1.08%, about 2.06 percentage points lower than the CSI 300 index in the same period; Among the segments, only biological products and APIs recorded negative returns, down 0.01% and 1.64% respectively; Pharmaceutical commerce, medical devices, chemicals, traditional Chinese medicine and medical services increased by 4.53%, 1.84%, 1.56%, 1.44% and 1.4% respectively; About 42% of the stocks in the industry recorded positive returns and about 58% of the stocks recorded negative returns.
This week, the pharmaceutical and biological industry saw a slight net inflow. From December 6 to December 10, 2021, the land stock connect had a net inflow of 48.834 billion yuan, of which the Shanghai Stock connect and Shenzhen Stock connect had a net inflow of 30.067 billion yuan and 18.767 billion yuan respectively. Among the Shenwan level industries, food and beverage, non bank finance and banks rank first in net inflow, with a net inflow of more than 8 billion yuan. This week, the pharmaceutical and biological industry had a net inflow of 282 million yuan, ranking eighth in the Shenwan industry, and the net inflow decreased compared with last week.
Industry news: this week, Progress has been made in the field of covid-19 treatment and prevention in the world: (1) the China food and drug administration has approved the registration application for the covid-19 virus neutralizing antibody combination therapy drugs ambavizumab and romisivir mAb of Tengsheng Huachuang under Tengsheng Bo pharmaceutical, and approved the combination of the above two drugs for the treatment of adults and adolescents with corresponding conditions (12~17 years old, weighing more than 40kg) infected with New Coronavirus. (2) AstraZeneca announced that its long-acting COVID-19 virus neutralizing antibody Evusheld was authorized by the US FDA emergency use for pre exposure prevention of COVID-19 exposure in specific adults and adolescents. (3) Lilly announced that the FDA has expanded the EUA of neutralizing antibody combination therapy, etcivir and banivir, to include specific high-risk pediatric populations (from birth to under 12 years of age). (4) Pfizer (Pfizer) and biontech announced that FDA has expanded the EUA of mRNA covid-19 vaccine booster needle to allow people over 16 years old to receive booster needle vaccination at least 6 months after completing two doses of vaccine.
Maintain recommended ratings for the industry. Pay attention to CXO, which is expected to continue, For example, Wuxi Apptec Co.Ltd(603259) (603259), Hangzhou Tigermed Consulting Co.Ltd(300347) (300347), Pharmaron Beijing Co.Ltd(300759) (300759), Joinn Laboratories (China) Co.Ltd(603127) (603127), Shanghai Medicilon Inc(688202) (688202), Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) (688621), Asymchem Laboratories (Tianjin) Co.Ltd(002821) (002821), Kyushu Pharmaceutical (603456), Porton Pharma Solutions Ltd(300363) (300363), Pharmablock Sciences (Nanjing) Inc(300725) (300725), etc. for scientific services, pay attention to Sino Biological Inc(301047) (301047), Nanjing Vazyme Biotech Co.Ltd(688105) (688105), etc. in terms of medical devices: focus on platform faucets Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (300760), medical beauty faucets Imeik Technology Development Co.Ltd(300896) (300896), ophthalmic device faucets Autek China Inc(300595) (300595), Eyebright Medical Technology(Beijing) Co.Ltd(688050) (688050), pharmaceutical equipment faucets Tofflon Science And Technology Group Co.Ltd(300171) (300171) and Truking Technology Limited(300358) (300358), rehabilitation medical device faucets Xiangyumedicalco.Ltd(688626) (688626), Nanjing Vishee Medical Technology Co.Ltd(688580) (688580), etc. leading retail pharmacies Dashenlin Pharmaceutical Group Co.Ltd(603233) (603233), Yifeng Pharmacy Chain Co.Ltd(603939) (603939), Yixintang Pharmaceutical Group Co.Ltd(002727) (002727), Lbx Pharmacy Chain Joint Stock Company(603883) (603883), etc., which are expected to benefit from the dual channel of negotiated drugs in the short term, and the performance growth is expected to pick up.
Risk tips: repeated epidemic, R & D failure, intensified industry competition, product safety and quality risk, etc.
